Keros Therapeutics, Inc.
KROS
$9.93
-$0.14-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -115.97% | 49.03% | 86.25% | 32.17% | 444.32% |
| Total Depreciation and Amortization | 17.15% | 20.48% | 25.80% | 20.92% | 24.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.65% | -18.87% | -51.01% | -0.09% | 12.34% |
| Change in Net Operating Assets | 341.82% | -20.55% | -56.60% | -111.50% | 128.91% |
| Cash from Operations | -102.19% | 40.68% | 110.65% | 25.57% | 461.69% |
| Capital Expenditure | 87.08% | 53.63% | 65.80% | -132.26% | 40.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 87.08% | 53.63% | 65.80% | -132.26% | 40.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 75.00% | -99.83% | -99.91% | -99.53% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -58,000.00% | -601.21% | -99.91% | -99.52% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -103.68% | -1,488.37% | -97.40% | 17.10% | 44.31% |